Given the variety of molecular consequences evoked by these inhibitors, inhibition of SIRT1 and oncogenic HSP90 circuit will likely collapse cellular epichaperomes and disturb the broad spectrum of their subordinate processes, decreasing cancer cell metabolic fitness, proliferation and viability. The gene discussed is SIRT1; the disease is cancer.